Emmanuelle Tresch‐Bruneel

Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial

Isabelle Laure Ray-Coquard, Julien Dômont, Emmanuelle Tresch‐Bruneel et al. · Journal of Clinical Oncology · 2015 · 188 citations · Full text

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)

Emmanuelle Bompas, Axel Le Cesne, Emmanuelle Tresch‐Bruneel et al. · Annals of Oncology · 2015 · 115 citations · Full text

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial

Axel Le Cesne, Jean‐Yves Blay, Julien Dômont et al. · The Lancet Oncology · 2015 · 94 citations

Surgical Oncology, Soft-tissue Sarcoma, Randomised Phase 2 +2

<scp>REGOSARC</scp>: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis

Vincent Berry, Laurent Basson, Emilie Bogart et al. · Cancer · 2017 · 42 citations · Full text

Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients

Athanasios Kakkos, L. Bresson, Delphine Hudry et al. · European Journal of Surgical Oncology · 2016 · 41 citations

Surgical Oncology, Venous Disease, Complication-related Removal +6